MINERVA SURGICAL INC

2021 Q4 Form 10-Q Financial Statement

#000095017021005019 Filed on December 02, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.61M $6.128M $11.62M
YoY Change
Cash & Equivalents $40.61M $6.128M $9.640M
Short-Term Investments
Other Short-Term Assets $149.0K $170.0K $9.962M
YoY Change -58.95%
Inventory $15.68M $14.96M $12.57M
Prepaid Expenses $1.264M $1.794M
Receivables $7.292M $6.758M $7.387M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $75.00M $39.87M $41.54M
YoY Change 65.13%
LONG-TERM ASSETS
Property, Plant & Equipment $4.594M $3.791M $4.002M
YoY Change 59.51%
Goodwill
YoY Change
Intangibles $37.01M
YoY Change
Long-Term Investments
YoY Change
Other Assets $524.0K $524.0K $615.0K
YoY Change
Total Long-Term Assets $40.09M $41.32M $43.67M
YoY Change -14.02%
TOTAL ASSETS
Total Short-Term Assets $75.00M $39.87M $41.54M
Total Long-Term Assets $40.09M $41.32M $43.67M
Total Assets $115.1M $81.19M $85.20M
YoY Change 25.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.629M $8.451M $6.453M
YoY Change 3.51%
Accrued Expenses $10.66M $11.38M $13.48M
YoY Change 4.49%
Deferred Revenue $206.0K $262.0K
YoY Change -5.94%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $189.0K $12.66M $0.00
YoY Change -88.67%
Total Short-Term Liabilities $22.81M $66.27M $52.45M
YoY Change -31.44%
LONG-TERM LIABILITIES
Long-Term Debt $39.09M $18.22M $100.4M
YoY Change 32.84%
Other Long-Term Liabilities $9.094M $31.87M $54.46M
YoY Change
Total Long-Term Liabilities $39.09M $18.22M $154.8M
YoY Change 32.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.81M $66.27M $52.45M
Total Long-Term Liabilities $39.09M $18.22M $154.8M
Total Liabilities $70.99M $205.3M $207.3M
YoY Change -62.76%
SHAREHOLDERS EQUITY
Retained Earnings -$249.6M -$260.4M
YoY Change 9.41%
Common Stock $28.00K $3.000K
YoY Change 2700.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $44.10M -$247.4M -$245.3M
YoY Change
Total Liabilities & Shareholders Equity $115.1M $81.19M $85.20M
YoY Change 25.04%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001452965
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40919
dei Entity Registrant Name
EntityRegistrantName
MINERVA SURGICAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3422906
dei Entity Address Address Line1
EntityAddressAddressLine1
4255 Burton Dr.
dei Entity Address City Or Town
EntityAddressCityOrTown
Santa Clara
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95054
dei City Area Code
CityAreaCode
855
dei Local Phone Number
LocalPhoneNumber
646-7874
dei Security12b Title
Security12bTitle
Common Stock, $ 0.001 par value
dei Trading Symbol
TradingSymbol
UTRS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28815941
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6128000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17359000
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
7283000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
7203000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6758000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8379000
CY2021Q3 us-gaap Inventory Net
InventoryNet
14960000
CY2020Q4 us-gaap Inventory Net
InventoryNet
10201000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4740000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2279000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
39869000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
45421000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
524000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
604000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
37005000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
43141000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3791000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2880000
CY2021Q3 us-gaap Assets
Assets
81189000
CY2020Q4 us-gaap Assets
Assets
92046000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8451000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3506000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2859000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2889000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11377000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10204000
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
15919000
CY2021Q3 utrs Delayed Cash Purchase Consideration
DelayedCashPurchaseConsideration
15000000
CY2020Q4 utrs Delayed Cash Purchase Consideration
DelayedCashPurchaseConsideration
15000000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
12659000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1668000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
66265000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33267000
CY2021Q3 utrs Redeemable Convertible Preferred Stock Warrant Liability Noncurrent
RedeemableConvertiblePreferredStockWarrantLiabilityNoncurrent
577000
CY2020Q4 utrs Redeemable Convertible Preferred Stock Warrant Liability Noncurrent
RedeemableConvertiblePreferredStockWarrantLiabilityNoncurrent
42000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
18222000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29423000
CY2021Q3 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
62500000
CY2020Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
46500000
CY2021Q3 utrs Convertible Notes Payables
ConvertibleNotesPayables
88960000
CY2020Q4 utrs Convertible Notes Payables
ConvertibleNotesPayables
66196000
CY2021Q3 utrs Derivative Liability Related To Related Parties
DerivativeLiabilityRelatedToRelatedParties
14400000
CY2020Q4 utrs Derivative Liability Related To Related Parties
DerivativeLiabilityRelatedToRelatedParties
23600000
CY2021Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
22764000
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
38007000
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
8528000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
23667000
CY2021Q3 us-gaap Liabilities
Liabilities
205316000
CY2020Q4 us-gaap Liabilities
Liabilities
190602000
CY2021Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
121732397
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
121732397
CY2021Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
12397838
CY2021Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
12397838
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
12397838
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
12397838
CY2021Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
136168000
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
136168000
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
123255000
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
123255000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
144406928
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
144406928
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3149777
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3149777
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1192299
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1192299
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
12968000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6269000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-260364000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-228092000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-247382000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-221811000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
81189000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92046000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12506000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12280000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38458000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24219000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5373000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5725000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15760000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13284000
CY2021Q3 us-gaap Gross Profit
GrossProfit
7133000
CY2020Q3 us-gaap Gross Profit
GrossProfit
6555000
us-gaap Gross Profit
GrossProfit
22698000
us-gaap Gross Profit
GrossProfit
10935000
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7919000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6722000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
22883000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16205000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3987000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1804000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18115000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5888000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1367000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1200000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4191000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2151000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
13273000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
9726000
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-4000
CY2020Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-1000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-544000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
75000
us-gaap Operating Expenses
OperatingExpenses
45189000
us-gaap Operating Expenses
OperatingExpenses
24244000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3225000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7324000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32272000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12024000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-132000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6140000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3171000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22491000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13309000
us-gaap Investment Income Interest
InvestmentIncomeInterest
80000
CY2021Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
1300000
CY2020Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
1300000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
4200000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
3200000
CY2021Q3 us-gaap Interest Expense
InterestExpense
3611000
CY2020Q3 us-gaap Interest Expense
InterestExpense
3293000
us-gaap Interest Expense
InterestExpense
10663000
us-gaap Interest Expense
InterestExpense
8714000
CY2021Q3 utrs Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
23383000
CY2020Q3 utrs Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
-859000
utrs Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
15243000
utrs Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
9201000
utrs Gain Loss On Bargain Purchase
GainLossOnBargainPurchase
643000
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-16853000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-16853000
utrs Gain Loss On Extinguishment Of Payroll Protection Program Loan
GainLossOnExtinguishmentOfPayrollProtectionProgramLoan
3036000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3225000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7324000
us-gaap Net Income Loss
NetIncomeLoss
-32272000
us-gaap Net Income Loss
NetIncomeLoss
-11892000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.15
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.33
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-12.56
CY2021Q3 utrs Weighted Average Shares Used In Computing Net Loss Per Share Basic And Diluted
WeightedAverageSharesUsedInComputingNetLossPerShareBasicAndDiluted
2798146
CY2020Q3 utrs Weighted Average Shares Used In Computing Net Loss Per Share Basic And Diluted
WeightedAverageSharesUsedInComputingNetLossPerShareBasicAndDiluted
999091
utrs Weighted Average Shares Used In Computing Net Loss Per Share Basic And Diluted
WeightedAverageSharesUsedInComputingNetLossPerShareBasicAndDiluted
2145733
utrs Weighted Average Shares Used In Computing Net Loss Per Share Basic And Diluted
WeightedAverageSharesUsedInComputingNetLossPerShareBasicAndDiluted
946576
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-221811000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
886000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14948000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-235742000
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
643000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3342000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2213000
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
5395000
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
5130000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40000
CY2021Q2 utrs Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
15000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4478000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-14099000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-245308000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
37000
CY2021Q3 utrs Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
39000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1075000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3225000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-247382000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-204524000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
150000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
5732000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-198618000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
42000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
399000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-10300000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-208477000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
205000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7324000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-215571000
us-gaap Profit Loss
ProfitLoss
-32272000
us-gaap Profit Loss
ProfitLoss
-11892000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-16853000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7948000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4415000
utrs Gain On Extinguishment Of Paycheck Protection Program Loan
GainOnExtinguishmentOfPaycheckProtectionProgramLoan
3036000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
5684000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
754000
utrs Change In Fair Value Of Redeemable Convertible Preferred Stock Warrant Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockWarrantLiability
-535000
utrs Change In Fair Value Of Redeemable Convertible Preferred Stock Warrant Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockWarrantLiability
34000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
780000
us-gaap Derivative Fair Value Hedge Included In Effectiveness Gain Loss
DerivativeFairValueHedgeIncludedInEffectivenessGainLoss
15243000
us-gaap Derivative Fair Value Hedge Included In Effectiveness Gain Loss
DerivativeFairValueHedgeIncludedInEffectivenessGainLoss
9201000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-132000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1621000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4820000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6600000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-5325000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2461000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1914000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
7807000
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
7698000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13935000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4951000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-723000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1227000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1000000
us-gaap Increase Decrease In Workers Compensation Liabilities
IncreaseDecreaseInWorkersCompensationLiabilities
-30000
us-gaap Increase Decrease In Workers Compensation Liabilities
IncreaseDecreaseInWorkersCompensationLiabilities
-48000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11306000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10570000
us-gaap Payments To Acquire Business Two Net Of Cash Acquired
PaymentsToAcquireBusinessTwoNetOfCashAcquired
15000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
888000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
726000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-888000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15726000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
963000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
91000
us-gaap Proceeds From Issuance Of Long Term Debt And Capital Securities Net
ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet
17959000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
963000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18050000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11231000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8246000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25166000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34783000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13935000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26537000
CY2021Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
6128000
CY2020Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
18839000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26537000
us-gaap Interest Paid Net
InterestPaidNet
1894000
us-gaap Interest Paid Net
InterestPaidNet
1338000
utrs Forgiveness Of Ppp Loan
ForgivenessOfPPPLoan
-3036000
utrs Issuance Of Derivative Instruments Related To Convertible Notes
IssuanceOfDerivativeInstrumentsRelatedToConvertibleNotes
6849000
us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
57222000
utrs Fair Value Of Contingent Consideration In Connection To Business Combination
FairValueOfContingentConsiderationInConnectionToBusinessCombination
23842000
utrs Fair Value Of Delayed Cash Consideration In Connection To Business Combination
FairValueOfDelayedCashConsiderationInConnectionToBusinessCombination
15000000
utrs Issuance Of Series D Redeemable Convertible Preferred Stock In Connection To Business Combination
IssuanceOfSeriesDRedeemableConvertiblePreferredStockInConnectionToBusinessCombination
2737000
utrs Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
54000
utrs Reclassification Of Inventory To Property And Equipment For Customer Usage Agreements
ReclassificationOfInventoryToPropertyAndEquipmentForCustomerUsageAgreements
1934000
utrs Reclassification Of Inventory To Property And Equipment For Customer Usage Agreements
ReclassificationOfInventoryToPropertyAndEquipmentForCustomerUsageAgreements
264000
us-gaap Net Income Loss
NetIncomeLoss
-32300000
us-gaap Net Income Loss
NetIncomeLoss
-11900000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-260400000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6100000
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
24447000
CY2021Q3 utrs Redeemable Convertible Preferred Stock Warrant Liability
RedeemableConvertiblePreferredStockWarrantLiability
577000
CY2021Q3 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
47788000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant estimates and assumptions include accounts receivable allowances, inventory allowances, recoverability of long-term assets, valuation of equity instruments and equity-linked instruments, valuation of common stock, stock-based compensation, valuation of the redeemable convertible preferred stock warrant liability and derivative liabilities, valuation and estimated useful lives of intangible assets, deferred tax assets and related valuation allowances, and impact of contingencies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (FDIC) insured limits.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company earns revenue from sale of disposable devices and controllers to customers such as hospitals, ambulatory surgical centers and physician offices. The Company’s accounts receivable are derived from revenue earned from customers. The Company performs ongoing credit evaluations of its customers’ financial condition and generally requires no collateral from its customers. At September 30, 2021 and 2020, and for the periods then ended, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customer accounted for more than 10.0% of accounts receivable or revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of suppliers </span></span><span style=""/></p><div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company purchases certain components of its products from a single or small number of suppliers. A change in or loss of these suppliers could cause a delay in filling customer orders and a possible loss of sales, which could adversely affect results of operations; however, management believes that suitable replacement suppliers could be obtained in such an event</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div>
utrs Number Of Customer Accounted For Accounts Receivable Or Revenue
NumberOfCustomerAccountedForAccountsReceivableOrRevenue
0
utrs Number Of Customer Accounted For Accounts Receivable Or Revenue
NumberOfCustomerAccountedForAccountsReceivableOrRevenue
0
utrs Concentration Of Suppliers
ConcentrationOfSuppliers
<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of suppliers </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company purchases certain components of its products from a single or small number of suppliers. A change in or loss of these suppliers could cause a delay in filling customer orders and a possible loss of sales, which could adversely affect results of operations; however, management believes that suitable replacement suppliers could be obtained in such an event</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
CY2021Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2500000
CY2021Q3 utrs Percentage Of Revenue From Contract With Customer Excluding Assessed Tax
PercentageOfRevenueFromContractWithCustomerExcludingAssessedTax
1
CY2020Q3 utrs Percentage Of Revenue From Contract With Customer Excluding Assessed Tax
PercentageOfRevenueFromContractWithCustomerExcludingAssessedTax
1
utrs Percentage Of Revenue From Contract With Customer Excluding Assessed Tax
PercentageOfRevenueFromContractWithCustomerExcludingAssessedTax
1
utrs Percentage Of Revenue From Contract With Customer Excluding Assessed Tax
PercentageOfRevenueFromContractWithCustomerExcludingAssessedTax
1
utrs Percentage Of Revenue Subject To Point In Time Recognition
PercentageOfRevenueSubjectToPointInTimeRecognition
0.990
utrs Percentage Of Revenue Subject To Point In Time Recognition
PercentageOfRevenueSubjectToPointInTimeRecognition
0.990
CY2021Q3 utrs Percentage Of Revenue Subject To Point In Time Recognition
PercentageOfRevenueSubjectToPointInTimeRecognition
0.990
CY2020Q3 utrs Percentage Of Revenue Subject To Point In Time Recognition
PercentageOfRevenueSubjectToPointInTimeRecognition
0.990
utrs Minimum Percentage Of Sale Extended Warranties On Capital Equipment
MinimumPercentageOfSaleExtendedWarrantiesOnCapitalEquipment
0.010
utrs Maximum Percentage Of Total Revenue Derived From Sale Of Single Use Disposable Products
MaximumPercentageOfTotalRevenueDerivedFromSaleOfSingleUseDisposableProducts
0.950
CY2021Q3 us-gaap Contract With Customer Receivable Allowance For Credit Loss
ContractWithCustomerReceivableAllowanceForCreditLoss
6758000
CY2020Q4 us-gaap Contract With Customer Receivable Allowance For Credit Loss
ContractWithCustomerReceivableAllowanceForCreditLoss
8379000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
262000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
219000
CY2021Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
5640000
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
5640000
CY2021Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
22764000
CY2020Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
14638000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
14638000
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
38007000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
23667000
CY2020Q4 utrs Redeemable Convertible Preferred Stock Warrant Liability
RedeemableConvertiblePreferredStockWarrantLiability
42000
CY2020Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
61716000
utrs Estimated Time To Exit From Mandatory Prepayment Derivative Liability
EstimatedTimeToExitFromMandatoryPrepaymentDerivativeLiability
P0Y1M6D
us-gaap Servicing Assets And Servicing Liabilities At Fair Value Assumptions Used To Estimate Fair Value Discount Rate
ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate
0.185
utrs Fair Value Derivative Liabilities Expected Exit Date
FairValueDerivativeLiabilitiesExpectedExitDate
2021-10-31
CY2020 utrs Fair Value Derivative Liabilities Expected Exit Date
FairValueDerivativeLiabilitiesExpectedExitDate
2022-06-30
CY2021Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
5640000
CY2021Q3 us-gaap Cash
Cash
488000
CY2020Q4 us-gaap Cash
Cash
2721000
CY2020Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
14638000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6128000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17359000
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
9297000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5068000
CY2021Q3 utrs Inventory Component Materials
InventoryComponentMaterials
5663000
CY2020Q4 utrs Inventory Component Materials
InventoryComponentMaterials
5133000
CY2021Q3 us-gaap Inventory Net
InventoryNet
14960000
CY2020Q4 us-gaap Inventory Net
InventoryNet
10201000
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1794000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1794000
CY2021Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2505000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
271000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
122000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
170000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
363000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4740000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2279000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12577000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10664000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8786000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7784000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3791000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2880000
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
600000
CY2020Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
500000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1800000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1300000
CY2021Q3 us-gaap Finite Lived Trademarks Gross
FiniteLivedTrademarksGross
3969000
CY2020Q4 us-gaap Finite Lived Trademarks Gross
FiniteLivedTrademarksGross
3969000
CY2021Q3 utrs Finite Lived Developed Technology Gross
FiniteLivedDevelopedTechnologyGross
30819000
CY2020Q4 utrs Finite Lived Developed Technology Gross
FiniteLivedDevelopedTechnologyGross
30819000
CY2021Q3 us-gaap Finite Lived Customer Relationships Gross
FiniteLivedCustomerRelationshipsGross
13466000
CY2020Q4 us-gaap Finite Lived Customer Relationships Gross
FiniteLivedCustomerRelationshipsGross
13466000
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
48254000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
48254000
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
11249000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5113000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
37005000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
43141000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2000000.0
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2000000.0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3100000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2045000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3693000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3693000
CY2021Q3 utrs Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
14016000
CY2021Q3 utrs Finite Lived Future Amortization Of Intangible Assets Net
FiniteLivedFutureAmortizationOfIntangibleAssetsNet
37005000
CY2021Q3 utrs Accrued Contract Liability
AccruedContractLiability
262000
CY2020Q4 utrs Accrued Contract Liability
AccruedContractLiability
219000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
8182000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
5376000
CY2021Q3 us-gaap Accrued Vacation Current And Noncurrent
AccruedVacationCurrentAndNoncurrent
1379000
CY2020Q4 us-gaap Accrued Vacation Current And Noncurrent
AccruedVacationCurrentAndNoncurrent
1184000
CY2021Q3 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
857000
CY2020Q4 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
831000
CY2021Q3 utrs Accrued Commissions Current And Noncurrent
AccruedCommissionsCurrentAndNoncurrent
528000
CY2020Q4 utrs Accrued Commissions Current And Noncurrent
AccruedCommissionsCurrentAndNoncurrent
828000
CY2021Q3 utrs Other Accrued Personnel Related Expenses
OtherAccruedPersonnelRelatedExpenses
95000
CY2020Q4 utrs Other Accrued Personnel Related Expenses
OtherAccruedPersonnelRelatedExpenses
46000
CY2021Q3 utrs Accrued Compensation
AccruedCompensation
2859000
CY2020Q4 utrs Accrued Compensation
AccruedCompensation
2889000
CY2021Q3 utrs Accrued Litigation
AccruedLitigation
7203000
CY2020Q4 utrs Accrued Litigation
AccruedLitigation
7203000
CY2021Q3 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
1460000
CY2020Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
824000
CY2021Q3 utrs Accrued Sales And Use Taxes
AccruedSalesAndUseTaxes
612000
CY2020Q4 utrs Accrued Sales And Use Taxes
AccruedSalesAndUseTaxes
754000
CY2021Q3 utrs Accrued Deferred Rent
AccruedDeferredRent
322000
CY2020Q4 utrs Accrued Deferred Rent
AccruedDeferredRent
445000
CY2021Q3 utrs Accrual For Inventory In Transit
AccrualForInventoryInTransit
658000
CY2020Q4 utrs Accrual For Inventory In Transit
AccrualForInventoryInTransit
602000
CY2021Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
860000
CY2020Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
157000
CY2021Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
11377000
CY2020Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
10204000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
31200000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-12000000.0
CY2021Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
400000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1400000
CY2020Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
500000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
900000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
218000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
846000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
358000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1422000
CY2021Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000
CY2020Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
300000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000.0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-100000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
144406928
CY2021Q3 utrs Warrants To Purchase Redeemable Convertible Preferred Stock
WarrantsToPurchaseRedeemableConvertiblePreferredStock
77842
CY2020Q4 utrs Warrants To Purchase Redeemable Convertible Preferred Stock
WarrantsToPurchaseRedeemableConvertiblePreferredStock
77842
CY2021Q3 utrs Common Stock Options Issued And Outstanding
CommonStockOptionsIssuedAndOutstanding
2170894
CY2020Q4 utrs Common Stock Options Issued And Outstanding
CommonStockOptionsIssuedAndOutstanding
2466594
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
59187
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
67010
utrs Conversions Of Convertible Notes To Preferred Stock
ConversionsOfConvertibleNotesToPreferredStock
0
CY2020 utrs Conversions Of Convertible Notes To Preferred Stock
ConversionsOfConvertibleNotesToPreferredStock
0
CY2020Q4 utrs Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantNumber
67010
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2466594
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.61
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y2M15D
utrs Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized
1653955
utrs Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted
1784086
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1784086
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.25
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1957478
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.61
utrs Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited And Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedAndCancelled
122308
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
122308
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.48
CY2021Q3 utrs Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantNumber
59187
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2170894
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.31
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M9D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8283000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1451709
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y6M25D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5579000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2170894
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.31
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y10M9D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
8283000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
700000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1500000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5100000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.36
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10000000.0
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M3D
utrs Repurchase Of Common Stock
RepurchaseOfCommonStock
0
utrs Repurchase Of Common Stock
RepurchaseOfCommonStock
0
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
410788
CY2020 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
136032
utrs Share Based Compensation Arrangements By Share Based Payment Award Options Aggregate Exercise Prices Of Early Exercised Shares
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAggregateExercisePricesOfEarlyExercisedShares
300000
CY2020 utrs Share Based Compensation Arrangements By Share Based Payment Award Options Aggregate Exercise Prices Of Early Exercised Shares
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAggregateExercisePricesOfEarlyExercisedShares
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
300000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1075000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
205000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5684000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
754000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.729
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.759
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.616
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.752
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.006
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.011
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.003
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.007
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3225000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7324000
us-gaap Net Income Loss
NetIncomeLoss
-32272000
us-gaap Net Income Loss
NetIncomeLoss
-11892000
CY2021Q3 utrs Weighted Average Shares Used In Computing Net Loss Per Share Basic And Diluted
WeightedAverageSharesUsedInComputingNetLossPerShareBasicAndDiluted
2798146
CY2020Q3 utrs Weighted Average Shares Used In Computing Net Loss Per Share Basic And Diluted
WeightedAverageSharesUsedInComputingNetLossPerShareBasicAndDiluted
999091
utrs Weighted Average Shares Used In Computing Net Loss Per Share Basic And Diluted
WeightedAverageSharesUsedInComputingNetLossPerShareBasicAndDiluted
2145733
utrs Weighted Average Shares Used In Computing Net Loss Per Share Basic And Diluted
WeightedAverageSharesUsedInComputingNetLossPerShareBasicAndDiluted
946576
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.15
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.33
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-12.56
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2021Q3 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2020Q3 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0

Files In Submission

Name View Source Status
0000950170-21-005019-index-headers.html Edgar Link pending
0000950170-21-005019-index.html Edgar Link pending
0000950170-21-005019.txt Edgar Link pending
0000950170-21-005019-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
utrs-20210930.htm Edgar Link pending
utrs-20210930.xsd Edgar Link pending
utrs-20210930_cal.xml Edgar Link unprocessable
utrs-20210930_def.xml Edgar Link unprocessable
utrs-20210930_htm.xml Edgar Link completed
utrs-20210930_lab.xml Edgar Link unprocessable
utrs-20210930_pre.xml Edgar Link unprocessable
utrs-ex31_1.htm Edgar Link pending
utrs-ex31_2.htm Edgar Link pending
utrs-ex32_1.htm Edgar Link pending
utrs-ex32_2.htm Edgar Link pending
utrs-ex3_1.htm Edgar Link pending
utrs-ex3_2.htm Edgar Link pending